À retenir
Among 1144 people attending memory clinics in South Korea, the most active quartile had lower plasma ptau217 (estimate -0.14, P = .01) and neurofilament light (-0.12, P = .01) than the least active, and higher activity was linked to better cognitive scores. Physical activity was self-reported and measured at the same time as the outcomes, so it cannot show that activity protects the brain.
Study design
Étude transversale
Reading basis
Published abstract
Reading focus
Association & confounding
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Physical activity is considered a non-drug way to lower dementia risk, but its link with blood markers of Alzheimer disease is little studied. The authors examined how physical activity relates to plasma markers of amyloid, tau and neuronal injury, and to cognition, in people with and without cognitive impairment.
Population et méthode
Cross-sectional study of 1144 participants (mean age 70.9, SD 8.7; 65.0% female) recruited from multiple memory clinics in South Korea between May 2019 and May 2022. Physical activity came from the International Physical Activity Questionnaire in metabolic equivalent task minutes per week, split into quartiles (Q1 lowest to Q4 highest). Plasma Aβ42/40, ptau217, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were measured. Cognition was assessed with the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB), adjusted for age, sex, education and β-amyloid uptake.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Compared with the lowest quartile, the highest activity quartile had lower ptau217 (estimate -0.14, SE 0.06; P = .01) and NfL (-0.12, SE 0.05; P = .01).
- 2Higher activity quartiles had higher MMSE scores: Q2 0.93 (P = .003), Q3 0.82 (P = .009), Q4 0.94 (P = .004).
- 3They also had lower CDR-SB scores, meaning less impairment: Q2 -0.33 (P = .04), Q3 -0.37 (P = .02), Q4 -0.55 (P = .001).
- 4The associations were more pronounced in people aged 65 or older and in those with cognitive impairment than in younger or unimpaired people.
Limites et incertitude
- 1Cross-sectional: people with early cognitive decline may become less active, so lower activity could be a consequence rather than a cause, as the authors note.
- 2Participants were memory clinic patients in South Korea, and physical activity came from a questionnaire, which tends to be imprecise.
- 3The abstract does not report results for Aβ42/40 or GFAP, and the claim that activity works through tau and neurodegeneration is a hypothesis, not tested here. This reading is based on the abstract only.
Mise en perspective
Regular activity went together with better blood-marker profiles and test scores in this clinic population, which fits the broader idea that staying active is good for brain health. It does not show that exercise slows Alzheimer disease or changes these markers. Questions about memory belong with a doctor.
Vos données
Weekly active minutes and steps from a wearable are a rough, device-based counterpart to the questionnaire used here, but no wearable measures Alzheimer markers. Track activity trends over months on one device, and do not use it to judge your own brain health.
Comprendre ce type de preuve
Measurements are taken in the same period. Direction and causation usually cannot be determined; symptoms can change behaviour as well as the reverse.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Importance
Physical activity (PA) is a nonpharmacological intervention for dementia prevention. The association between PA and Alzheimer disease (AD) plasma biomarkers remains underexplored.
Objective
To investigate the associations among PA; plasma biomarkers, including β-amyloid 42/40 (Aβ42/40), phosphorylated-tau217 (ptau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL); and cognition.
Design, setting, and participants
This cross-sectional study included participants with and without cognitive impairment recruited from multiple memory clinics in South Korea between May 2019 and May 2022. Data were analyzed from June to December 2024.
Exposures
PA was assessed as metabolic equivalent task minutes per week using the International Physical Activity Questionnaire and categorized into quartiles from the lowest (Q1) to the highest (Q4).
Main outcomes and measures
Plasma Aβ42/40, ptau217, GFAP, and NfL were measured. Cognition was assessed using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB).
Results
Among 1144 participants (mean [SD] age 70.9 [8.7] years; 744 [65.0%] female), the highest PA quartile showed significantly lower ptau217 (estimate [SE], -0.14 [0.06]; P = .01) and NfL (estimate [SE], -0.12 [0.05]; P = .01) compared with the lowest quartile. Higher PA quartiles were associated with higher MMSE scores (estimate [SE]: Q2, 0.93 [0.31]; P = .003; Q3, 0.82 [0.32]; P = .009; Q4, 0.94 [0.32]; P = .004) and lower CDR-SB scores (estimate [SE]: Q2, -0.33 [0.16]; P = .04; Q3, -0.37 [0.16]; P = .02; Q4, -0.55 [0.16]; P = .001) after adjusting for age, sex, education years, and β-amyloid uptake. In subgroup analyses according to age and cognitive status, the associations of PA and plasma biomarkers with cognition were more pronounced in the older (age ≥65 years) and cognitively impaired groups compared with the younger and cognitively unimpaired groups.
Conclusions and relevance
These findings suggest that PA may help delay cognitive decline by modulating neurodegeneration and AD-specific tau pathologies. However, the cross-sectional design limits causal inference, and longitudinal studies are needed to confirm and clarify these associations.
Sources et attribution
Physical Activity, Alzheimer Plasma Biomarkers, and Cognition.
Kim SA, Shin D, Ham H, Kim Y, Gu Y, Kim HJ, Na DL, Zetterberg H, Blennow K, Seo SW, Jang H, Precision Medicine Platform for Mild Cognitive Impairment Based on Multi-omics, Imaging, Evidence-Based R&BD (PREMIER) Consortium.
JAMA network open · 2025-03-03
DOI: 10.1001/jamanetworkopen.2025.0096 ↗PubMed · 40042844 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
7,000 steps a day linked to lower risk of death, heart disease and dementia than 2,000
Compared with 2000 steps a day, 7000 steps was associated with a hazard ratio of 0.53 (95% CI 0.46 to 0.60) for all-cause mortality across 14 studies, 0.75 (0.67 to 0.85) for cardiovascular disease and 0.62 (0.53 to 0.73) for dementia; cancer incidence was not significantly different (0.94, 0.87 to 1.01). Several outcomes rest on only two to four studies, and the certainty of evidence ranged from moderate to very low.
The Lancet Public Health
Brief bursts of vigorous effort in daily life linked to lower mortality in non-exercisers
Among 25,241 UK Biobank adults who reported no leisure-time exercise, a median of 3 vigorous bouts of 1 or 2 minutes a day, picked up by a wrist accelerometer, was associated with a 38% to 40% lower risk of all-cause and cancer death and a 48% to 49% lower risk of cardiovascular death than no such bouts, over an average of 6.9 years and 852 deaths. This is an observational study using one week of wrist data and an algorithm to define vigorous effort, so it cannot show that adding such bursts causes the lower risk.
Nature Medicine
Steps and mortality: gains flatten near 6,000–8,000 (age 60+) and 8,000–10,000 (under 60)
Pooling 15 cohorts (47,471 adults, 3,013 deaths, median follow-up 7.1 years), the second, third and fourth quartiles of daily steps (medians 5,801, 7,842 and 10,901) had hazard ratios for death of 0.60, 0.55 and 0.47 against the lowest quartile (median 3,553). The curve flattened at about 6,000 to 8,000 steps a day for adults aged 60 and over and 8,000 to 10,000 for younger adults. The data are observational, from a single week of step counting, mostly with waist-worn research devices.
The Lancet Public Health
Accelerometers on 36,383 adults: any activity, even light, linked to lower mortality
In eight pooled cohorts (36,383 adults, mean age 62.6 years, 2,149 deaths over a median 5.8 years), the most active quarter by accelerometer-measured total activity had a mortality hazard ratio of 0.27 (95% CI 0.23 to 0.32) against the least active, and the most sedentary quarter had 2.63 (1.94 to 3.56). Light activity alone showed the same pattern, with 0.38 (0.28 to 0.51) in the top quarter. These are observational associations in adults aged 40 and over from the US and western Europe, so illness-driven inactivity and confounding cannot be excluded.
BMJ

